Dr. Nina Heiss

Medical Affairs: Cardiovascular, Diabetes, Thyroids, Endocrinology. Executed on global medical communication strategies across therapy areas Implemented and maximized tailored internal and external medical publication dissemination routes Accomplished direct engagement with journal editors Facilitated and guided regional and country trainings on medical publication strategies and operationalization of journal publications

Medical Affairs: Fertility, Endocrinology, General Medicine, Global Health. Led integrated Medical Communication Strategies across assigned life-cycle asset portfolios Accomplished strategic alignment and one voice scientific messages Developed and mediated successful implementation of Scientific Communication Platforms Demonstrated budget accountability Led team to compliance and audit readiness Accomplished KPI reporting in assigned area of responsibility Recruited, led, developed, and promoted people

Oncology. Led integrated Medical Communication Strategies for launching and late-stage assets in assigned tumor indications (NSCLC, CRC, SCCHN) Accomplished operationalization of medical communication strategy Innovated and delivered on new digital approaches to enhance multichannel medical communication experience Guided medical information vendor change management Supported transformation of Global Medical Communication department Led team of senior and junior people

Oncology. Drove and implemented LEAN medical publication process Led long-term medical publication strategy for core product Accomplished and executed on delivery of medical publications Developed and implemented key scientific statements documents Created and led global-local community of best practice Demonstrated KPI tracking of cost, quality and timelines Led a team of three to eight people

Oncology, Commercial and Marketing. Led and implemented Oncology Key Thought Leader strategy across pipeline Co-led Regulatory KTL stakeholder interaction management Led KTL engagement programs with multidisciplinary teams Established long-term internal and external partnerships (advisory board meetings, media/speaker trainings, medical education activities) Co-led compliance and legal framework of global KTL activities within the global environment and the affiliates Managed budgets

Oncology, Commercial and Marketing. Accomplished sales forecasts, commercial valuation, and risk assessment of early oncology assets Accomplished setting up target product profiles (TPPs) for early assets Supported assessment of in-licencing efforts Managed New Therapies budget Developed early branding concepts and messages Organized advisory board meetings and early key thought leader activities

Oncology. Led team of technicians, PhD and medical students, diploma students Identified biomarkers of drug response Led biomarker discovery, validation, and bio-banking into clinical trials Consulted strategic innovation team on molecular theranostics Participated and presented at Investigator & Advisory Board Meetings Led preclinical collaborations with external experts Accomplished conceptual evaluation of new targets

Conceptualized the foundation for implementing pharmacogenomics into drug development Performed technology & cost evaluation Acted as liaison to biomarker technology outsourcing companies Led Preclinical Target SNP Pilot Project Member of the Pharmacogenomic Task Forces of the Verband Forschender Arzneimittelhersteller (VFA) and EFPIA

Accomplished primary research that led to the mapping and sequencing of parts of the chromosomal region Xq28 Identified two new genes responsible for causing X-linked Dyskeratosis Congenita and Incontinentia Pigmenti when mutated Published in top-tier high-impact journals e.g. Nature, Nature Genetics, Blood